CHICAGO, May 29 /PRNewswire-FirstCall/ -- The Female Health Company (NYSE Amex: FHC) announced today that its Board of Directors has approved the decision to switch the listing of its common stock from the NYSE AMEX LLC to the NASDAQ Stock Market LLC. Effective as of the opening of trading on Tuesday, June 9, 2009 the Company's shares will commence trading on NASDAQ under the symbol [FHCO]. "This decision was reached after careful consideration of capital market alternatives and analysis of the electronic market model, which provides added visibility to our investors," said O.B. Parrish, Chairman and C.E.O. of The Female Health Company. "We believe that NASDAQ's electronic multiple market maker structure will provide our company with enhanced exposure and liquidity, while at the same time providing investors with the best prices, the fasted execution, and the lowest cost per trade. As the world's largest electronic stock market, NASDAQ promotes innovation and attracts leading growth companies from a diverse group of sectors. We are proud to be a part of the NASDAQ Stock Market." NASDAQ is the largest U.S. electronic stock market. With approximately 3,200 companies, it lists more companies and, on average, its systems trade more shares across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks. For more information about NASDAQ, visit the NASDAQ website at http://www.nasdaq.com/ or the NASDAQ Newsroom http://www.nasdaq.com/newsroom. About The Female Health Company The Female Health Company (FHC), headquartered in Chicago, IL, is the maker of the FC Female Condom (FC1 and FC2), a revolutionary option offering women dual protection against both sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. FHC was created as a worldwide company in February 1996 with the purchase of Chartex Resources Ltd., the holder of exclusive worldwide rights to FC1. The Company holds exclusive product and technology patents for FC1 in the United States, Australia, Brazil, Canada, France, Germany, Italy, Spain, the United Kingdom, the People's Republic of China, South Korea and Japan. FC2 patents have been granted in Australia and South Africa and are pending in various other countries. FHC is the sole manufacturer and marketer of the FC1 and FC2 female condoms in the world. The Female Health Company and its partners currently market the Female Condom under FC Female Condom(R), FC2 Female Condom(R), Reality(R), Femidom(R), Femy(R), and Care(R). "Safe Harbor" statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated. For more information about the Female Health Company visit the Company's web site at http://www.femalehealth.com/ and http://www.femalecondom.org/. If you would like to be added to an e-mail alert list, please send an e-mail to DATASOURCE: The Female Health Company CONTACT: William R. Gargiulo, Jr., +1-231-526-1244, or Donna Felch, +1-312-595-9123, both of The Female Health Company Web Site: http://www.femalehealth.com/ http://www.femalecondom.org/ http://www.nasdaq.com/

Copyright